Ranbaxy still under attack in India amid WHO all clear
This article was originally published in Scrip
Ranbaxy continues to be under fire in India, with reports of a prominent pharmacy chain issuing an advisory against its products and the likelihood of a public interest litigation seeking the cancellation of the firm's manufacturing licence coming up for hearing in the Supreme Court next week.
You may also be interested in...ï»¿
Pharma manufacturing is operating well below normal levels in India, disrupted by labor absenteeism and supply chain issues amid the ongoing lock-down in the country, though the government is actively engaged in addressing bottlenecks. A speedy recovery is vital not just for domestic supplies.
Indian drug makers appear confident of meeting both domestic and global requirements for hydroxychloroquine sulphate after India relaxed export curbs on the product, subject to strict monitoring, against the backdrop of requests from global heads of government for supplies of the potential treatment for COVID-19.
The termination of the Aurobindo-Sandoz deal isn’t perhaps all bad news for the Indian firm and the flip side may be an improved balance sheet, according to some analysts. But the resolution of compliance issues at manufacturing facilities remains critical.